Tags

  • Search

  • Sorting

  • Filters

The risky business of aflatoxins in milk

by | 0 Comments

If you’re in the dairy or food testing business, you know the threat aflatoxins pose. Aflatoxins are a type of mycotoxin produced by Aspergillus parasiticus, aspergillus flavus , and rarely aspergillus nomius.1 These are likely the most extensively researched group of mycotoxins because of their adverse health effects.2 What’s more, they are widely found in a variety of crops, namely maize, tree nuts, and spices. Believed to be primarily caused by rising temperatures and humidity, these naturally occurring fungi grow on crops in the field, or during storage of feed and raw materials, where they can potentially produce toxins that enter the food chain.

Overcoming uncertainty in your PFAS analysis

Overcoming uncertainty in your PFAS analysis

by | ,

Just like gum on the bottom of a shoe, the existence of per- and poly-fluorinated alkyl substances (PFAS) in our environment is a sticky one. If you’re in the field of environmental testing, then you’re all too familiar with the threat these substances have on public health. While we have learned a lot about them over the years, there is still much more to understand. With the right detection methods, we can gather the information we need to empower us to make informed decisions on reducing the risks they impose.

FDA’s final rule on LDTs: what does it mean for clinical laboratories?

FDA’s final rule on LDTs: what does it mean for clinical laboratories?

by | ,

On April 29, 2024, the U.S. Food and Drug Administration (FDA) announced a final rule regulating laboratory developed tests (LDTs) as in vitro diagnostic devices (IVDs) under the Federal Food, Drug and Cosmetic Act (FD&C Act). This rule amends FDA’s regulations to state that in vitro diagnostic tests “manufactured” by clinical laboratories fall within the scope of the FDA regulatory oversight and is poised to dramatically shift the way clinical diagnostic laboratories in the United States develop and offer LDTs in the future. Read this blog post for a basic overview of the scope, intent and implications of this final rule, including the regulatory requirements, exceptions and timeline for implementation.

Guide decisions during cell line development with more information at the intact level

Guide decisions during cell line development with more information at the intact level

by | , , ,

Monitoring product quality attributes (PQAs) throughout monoclonal antibody (mAb) development is vital to ensuring drug safety and efficacy. By adopting orthogonal analytical techniques and integrating new technologies that have the potential to provide more information, it is possible to improve product quality and manufacturing efficiency and make more informed decisions.

What has the Echo® MS system done for the pharma industry? (And don’t just take our word for it!)

What has the Echo® MS system done for the pharma industry? (And don’t just take our word for it!)

by | , , ,

SCIEX was very proud to have an illustration of the Acoustic Ejection Mass Spectrometry (AEMS) technology that powers the Echo® MS system on the front cover of the Journal of the American Society for Mass Spectrometry in January 2023. The associated article—Ultrahigh-Throughput Intact Protein Analysis with Acoustic Ejection Mass Spectrometry—was co-authored by scientists from SCIEX and Merck.

The Promise of Precision Medicine

by | , ,

Here is the latest update on the Worldwide Efforts to Accelerate Precision Medicine

The NIH recently issued a press release in early July announcing $55 million in awards. According to the release, the $55 million award in the fiscal year 2016 will go towards building the foundational partnerships and infrastructure needed to launch the Cohort Program of President Obama’s Precision Medicine Initiative (PMI). The PMI Cohort Program is a landmark longitudinal research effort that aims to engage 1 million or more U.S. participants to improve the ability to prevent and treat disease based on individual differences in lifestyle, environment, and genetics.

Why Study Lipids?

Why Study Lipids?

by | , ,

I had an opportunity to follow up with Steven M Watkins, Ph.D. to talk about the importance of studying lipids in disease. Steve has been working in the lipids field for over 20 years and is one of the foremost experts in lipid biology. Steve founded Lipomics in 2000, an early metabolomics company focused on quantitative lipidomics and had followed that company through a series of changes that led to its involvement in the clinical diagnostic development and global metabolomics. Steve authored over 70 peer-reviewed publications including several book chapters on lipids and lipid metabolism. His presentations on this topic are fascinating and very informative, so I wanted to capture some of his thinking here!

Improved complex sample processing for higher quality of results, reproducibility and depth of proteomic analysis

Improved complex sample processing for higher quality of results, reproducibility and depth of proteomic analysis

by | , ,

SCIEX partners to improve depth of proteome coverage
SCIEX and Pressure BioSciences address a major challenge for researchers performing complex sample preparation by marketing a complete solution to increase the depth, breadth, and reproducibility of protein extraction, digestion, and quantitation in all tissue types, especially challenging samples like tumors.

Industrialize Your Quantitative Proteomics Using a More Simplified Sample Prep

Industrialize Your Quantitative Proteomics Using a More Simplified Sample Prep

by |

in part 1 and part 2 of this blog series we discussed how you can increase your efficiency for high throughput quantitative proteomics by industrializing your sample analysis and data processing. Microflow SWATH® Acquisition on your TripleTOF® system coupled with OneOmics™ data analysis tools allow you to run samples faster, collect data faster, and process your data files faster. It all adds up to getting more meaningful biological information in a shorter amount of time.

Industrialize Your Quantitative Proteomics Using a More Simplified Sample Prep

Industrialize Your Quantitative Proteomics with the OneOmics Project

by | , ,

For many labs, the days are long gone when it was acceptable to run only a few samples a week for your quantitative proteomics projects. The pressure for faster turn-around times, to support larger cohort studies, to sustain multiple research directions, and to transition from a purely unbiased discovery mode to verifying something truly unique and interesting, all demand a faster pace. Many labs are now being asked to analyze a hundred samples a week or more. In part 1 of this blog series, we saw how moving to a microflow SWATH workflow can dramatically increase your throughput with little compromise on overall results. In this part, we’ll address what to do with all of this data because it’s just no good if all we’ve done is move the bottleneck downstream.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

SCIEX Now™ support network
The destination for all your support needs.
Contact support
Wordpress Social Share Plugin powered by Ultimatelysocial